Kiniksa Pharmaceuticals International, plc (KNSA): Operating Cash Flow
$137.99M
Year ended 2025-12-31
$165.86M
Trailing 12 months to 2026-03-31
+187.5%
3-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $137.99M | +437.1% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $25.69M | +93.1% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $13.30M | +129.1% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $5.81M | n/m | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | -$126.30M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$136.53M | n/m | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | -$158.37M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$81.01M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$50.22M | n/a | 2019-03-12, From 2017-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $137.99M | +437.1% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$466.00M | n/m |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $47.33M | -72.5% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | -$93.41M | n/m |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $156.12M | -26.8% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $151.99M | -19.7% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $170.60M | +190.6% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | -$24.77M | n/m |
| Opko Health, Inc. (OPK) | 2025-12-31 | -$178.54M | n/m |
Compare KNSA, RARE, SUPN, AXSM side by side · Screen every company in Pharmaceutical Preparations ↗